Heart drug study halted early: limited data on right heart changes
NCT ID NCT04954742
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether the drug riociguat could improve right heart size and function in people with two types of pulmonary hypertension (PAH and CTEPH). It planned to enroll 30 adults, but was terminated early, so results are limited. The goal was to use echocardiograms to measure changes in the heart's right chambers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital
Heidelberg, 69126, Germany